Analytical accuracy in gender-affirming care hinges on assays that defy traditional binary ranges. Clinical labs must select diagnostic test kits with a broad dynamic range capable of quantifying hormones across male and female physiological spectrums—from suppressed testosterone in transgender women to elevated levels in transgender men. Equally critical is applying sex-specific reference intervals aligned to the patient’s affirmed gender, not their sex assigned at birth, to prevent dangerous diagnostic errors like false anemia flags.
The core challenge is this: standard “male” and “female” reference intervals were built for cisgender physiology. In gender-affirming therapy, labs must re-think both the analytical performance of their assays and the clinical context of their reports to deliver safe, meaningful results. The solution is a dual focus on wide-range assay validation and patient-centered, target-profile reference intervals.
Why Routine Assays Fail in Gender-Affirming Care
The Dynamic Range Imperative
Monitoring hormone therapy requires measuring serum 17β-estradiol and total testosterone every three months, often alongside hemoglobin, creatinine, and lipid panels. The physiological goal is to suppress endogenous hormones and achieve levels typical of the patient’s affirmed gender. This creates two technical problems for a conventional assay.
First, a kit designed for cisgender men may not accurately detect the low testosterone concentrations targeted in transgender women. Conversely, an assay calibrated for cisgender women might saturate or lose linearity at the elevated testosterone levels typical in transgender men. A broad dynamic range, validated at both extremes, is non-negotiable.
The Reference Interval Trap
Even if an assay measures a hormone correctly, the wrong reference interval can cause harm. For a transgender woman on estrogen, a lab report that uses male reference intervals might flag her low testosterone as “abnormally low” and trigger unnecessary investigation. For a transgender man, the same male interval could mask genuine polycythemia if his testosterone-driven hemoglobin is compared to female norms, leading to a missed diagnosis.
Sex-specific reference intervals must match the target hormone profile. The lab’s information system must be flexible enough to suppress default intervals and apply the appropriate clinical context—otherwise, the clinician receives a report that is technically accurate but clinically misleading.
Assay Performance Standards That Protect Patients
Why Calibrator Standardisation Matters
The challenges seen with human growth hormone (hGH) and anti-Müllerian hormone (AMH) immunoassays offer a stark warning. For years, hGH assays used legacy pituitary-derived standards (IS 80/505), yielding inconsistent results. The shift to recombinant 22 kDa hGH preparations (IRP 98/574) improved batch-to-batch purity and enabled mass-unit reporting, but also introduced bias against patient serum containing other GH forms. Manufacturers had to evaluate calibrant recovery and assess product bias against All-Lab Trimmed Mean (ALTM) benchmarks to ensure consistency.
The lesson for estradiol and testosterone testing is clear: choose assays aligned with international reference materials and validated for commutability with patient samples. Without this, bias can vary from -30% to +10% across methods, undermining clinical decisions.
Kit-Specific Reference Ranges and Unit Standardisation
The AMH story reinforces another principle. Because no universal standard existed, numerical values differed wildly between commercial kits. Developers had to establish kit-specific reference ranges and clinical cut-offs rather than assume platform equivalence. They also had to standardize unit expression using the conversion 1 ng/mL = 7.14 pmol/L.
For sex hormones, labs must do the same. Whenever a new reagent lot or platform is introduced, verify that the reference intervals remain valid for transgender populations. If the vendor does not provide transgender-specific data, the lab should generate its own verification using samples from stable patients on therapy.
Antibody Selection and Matrix Effects
Just as hGH antibody raw materials must recognize both recombinant calibrator and endogenous forms, estradiol and testosterone immunoassays must be carefully evaluated for cross-reactivity with structurally similar molecules and for matrix effects in patient serum. Mass spectrometry-based methods often outperform immunoassays in specificity, especially at low concentrations, and can provide the dynamic range needed to span both suppressed and elevated levels.
Understanding the Trade-offs and Hidden Pitfalls
The Ambiguity of “Normal” in Transition
Applying affirmed-gender reference intervals assumes that a transgender woman’s estradiol target is identical to that of a premenopausal cisgender woman. Yet therapeutic ranges are often consensus-driven, not evidence-based, and may differ from physiological norms. Labs must communicate that reference intervals are guides, not rigid diagnostic boundaries.
Dynamic Range vs. Sensitivity
A kit with a wide dynamic range might sacrifice sensitivity at the low end. For monitoring suppressed testosterone, a limit of quantification of 0.1 nmol/L or lower is often essential. Labs should review method validation data specifically for lower limit of quantification (LLOQ) performance, not just the total analytical measuring range.
The Anemia Flag Paradox
The primary reference emphasizes false anemia flags. Transgender women on estrogen therapy may develop lower hemoglobin levels that, when compared to male reference intervals, look like anemia. But if her target profile is female, her hemoglobin is normal. Co-reporting hemoglobin with the correct gender-specific interval is a safety imperative that prevents unnecessary iron studies or referrals.
Making the Right Choice for Your Lab
Every clinical lab supporting gender-affirming care must balance technical capability with clinical empathy. The path depends on your primary focus.
- If your primary focus is analytical accuracy: Select assay platforms with certified reference material alignment and validate dynamic range across all clinically expected concentrations, from suppressed to supraphysiologic.
- If your primary focus is clinical safety: Implement a policy that ties all reported reference intervals to the patient’s affirmed gender and target hormone profile, with clear documentation to prevent misinterpretation.
- If your primary focus is operational consistency: Build a verification protocol for every new reagent lot, and establish kit-specific reference intervals for your transgender patient population—never assume cross-platform equivalence.
The right assay and the right reference interval together transform a lab value from a potential source of harm into a trusted tool for safe, affirming care.
Summary Table:
| Metric / Focus Area | Technical & Clinical Challenge | Recommended Standard / Strategy |
|---|---|---|
| Dynamic Range | Extreme low (suppressed) or high hormone concentrations | Validate linearity across broad male & female physiological ranges |
| Reference Intervals | Misleading flags using default assigned-sex intervals | Align reference ranges with affirmed gender and target hormone profiles |
| Standardisation | Inter-method bias up to 30% across commercial kits | Calibrate against certified reference materials & monitor ALTM benchmarks |
| Low-End Sensitivity | Inability to detect low testosterone in transgender women | Validate LLOQ (e.g., ≤ 0.1 nmol/L) alongside total measuring range |
Enhance your assay performance and ensure diagnostic accuracy for every patient population. CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to IVD raw materials, technical services, and consulting—covering every stage from concept to clinic. Whether you need high-specificity antibodies, reference material alignment, or technical validation support for wide dynamic ranges, contact us today to discover how we can advance your diagnostic development.